Cargando…
Impact of COVID-19 pandemic on screening and diagnosis of patients with prostate cancer: a systematic review protocol
INTRODUCTION: With the exponential progress of patients with COVID-19, unexpected restrictions were directed to limit SARS-CoV-2 dissemination and imposed health-system an entire reformation to diminish transmission risk. These changes likely have caused the full range of cancer screenings and diagn...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9421918/ https://www.ncbi.nlm.nih.gov/pubmed/36028267 http://dx.doi.org/10.1136/bmjopen-2022-063748 |
_version_ | 1784777702048268288 |
---|---|
author | Mostafavi Zadeh, Seyed Mostafa Tajik, Fatemeh Moradi, Yousef Kiani, Jafar Ghods, Roya Madjd, Zahra |
author_facet | Mostafavi Zadeh, Seyed Mostafa Tajik, Fatemeh Moradi, Yousef Kiani, Jafar Ghods, Roya Madjd, Zahra |
author_sort | Mostafavi Zadeh, Seyed Mostafa |
collection | PubMed |
description | INTRODUCTION: With the exponential progress of patients with COVID-19, unexpected restrictions were directed to limit SARS-CoV-2 dissemination and imposed health-system an entire reformation to diminish transmission risk. These changes likely have caused the full range of cancer screenings and diagnosis gaps. Regardless of the recommendations, prostate cancer (PCa) screening/diagnosis programmes were momentarily postponed. Prostate-specific antigen (PSA) testing has been an inexpensive, low-invasive and relatively precise means of detection for PCa screening that would improve the uncovering of any type of PCa. Unfortunately, a decrease in PSA screening would significantly decrease PCa detection, with non-negligible growth in PCa-specific death. This review is designed to improve our understanding of the impact of the COVID-19 pandemic on the screening and diagnosis of patients with PCa. METHODS AND ANALYSIS: This systematic review will be reported in accordant with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidance. A comprehensive search has been executed through five main electronic databases: PubMed/MEDLINE, Web of Science, Scopus, Embase and ProQuest until 1 March 2022. Besides, grey literature, preprint studies and references of included studies will be searched. The main keywords have been used to perform the search strategy: COVID-19, prostatic neoplasms. All the relevant studies that met the inclusion criteria will be screened, selected and then extracted data by two independent authors. The quality assessment of the included studies will be performed by the Newcastle-Ottawa Scale. In case of any disagreement between the two authors in selecting, extracting data and assessing the quality of included studies, it will be resolved via consensus and checked by the third author. ETHICS AND DISSEMINATION: As this study will be a systematic review without human participants’ involvement, there will be no requirement for ethics approval. Findings will be presented at conferences and in a peer-reviewed journal. PROSPERO REGISTRATION NUMBER: CRD42021291656. |
format | Online Article Text |
id | pubmed-9421918 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-94219182022-08-29 Impact of COVID-19 pandemic on screening and diagnosis of patients with prostate cancer: a systematic review protocol Mostafavi Zadeh, Seyed Mostafa Tajik, Fatemeh Moradi, Yousef Kiani, Jafar Ghods, Roya Madjd, Zahra BMJ Open Oncology INTRODUCTION: With the exponential progress of patients with COVID-19, unexpected restrictions were directed to limit SARS-CoV-2 dissemination and imposed health-system an entire reformation to diminish transmission risk. These changes likely have caused the full range of cancer screenings and diagnosis gaps. Regardless of the recommendations, prostate cancer (PCa) screening/diagnosis programmes were momentarily postponed. Prostate-specific antigen (PSA) testing has been an inexpensive, low-invasive and relatively precise means of detection for PCa screening that would improve the uncovering of any type of PCa. Unfortunately, a decrease in PSA screening would significantly decrease PCa detection, with non-negligible growth in PCa-specific death. This review is designed to improve our understanding of the impact of the COVID-19 pandemic on the screening and diagnosis of patients with PCa. METHODS AND ANALYSIS: This systematic review will be reported in accordant with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidance. A comprehensive search has been executed through five main electronic databases: PubMed/MEDLINE, Web of Science, Scopus, Embase and ProQuest until 1 March 2022. Besides, grey literature, preprint studies and references of included studies will be searched. The main keywords have been used to perform the search strategy: COVID-19, prostatic neoplasms. All the relevant studies that met the inclusion criteria will be screened, selected and then extracted data by two independent authors. The quality assessment of the included studies will be performed by the Newcastle-Ottawa Scale. In case of any disagreement between the two authors in selecting, extracting data and assessing the quality of included studies, it will be resolved via consensus and checked by the third author. ETHICS AND DISSEMINATION: As this study will be a systematic review without human participants’ involvement, there will be no requirement for ethics approval. Findings will be presented at conferences and in a peer-reviewed journal. PROSPERO REGISTRATION NUMBER: CRD42021291656. BMJ Publishing Group 2022-08-26 /pmc/articles/PMC9421918/ /pubmed/36028267 http://dx.doi.org/10.1136/bmjopen-2022-063748 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Oncology Mostafavi Zadeh, Seyed Mostafa Tajik, Fatemeh Moradi, Yousef Kiani, Jafar Ghods, Roya Madjd, Zahra Impact of COVID-19 pandemic on screening and diagnosis of patients with prostate cancer: a systematic review protocol |
title | Impact of COVID-19 pandemic on screening and diagnosis of patients with prostate cancer: a systematic review protocol |
title_full | Impact of COVID-19 pandemic on screening and diagnosis of patients with prostate cancer: a systematic review protocol |
title_fullStr | Impact of COVID-19 pandemic on screening and diagnosis of patients with prostate cancer: a systematic review protocol |
title_full_unstemmed | Impact of COVID-19 pandemic on screening and diagnosis of patients with prostate cancer: a systematic review protocol |
title_short | Impact of COVID-19 pandemic on screening and diagnosis of patients with prostate cancer: a systematic review protocol |
title_sort | impact of covid-19 pandemic on screening and diagnosis of patients with prostate cancer: a systematic review protocol |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9421918/ https://www.ncbi.nlm.nih.gov/pubmed/36028267 http://dx.doi.org/10.1136/bmjopen-2022-063748 |
work_keys_str_mv | AT mostafavizadehseyedmostafa impactofcovid19pandemiconscreeninganddiagnosisofpatientswithprostatecancerasystematicreviewprotocol AT tajikfatemeh impactofcovid19pandemiconscreeninganddiagnosisofpatientswithprostatecancerasystematicreviewprotocol AT moradiyousef impactofcovid19pandemiconscreeninganddiagnosisofpatientswithprostatecancerasystematicreviewprotocol AT kianijafar impactofcovid19pandemiconscreeninganddiagnosisofpatientswithprostatecancerasystematicreviewprotocol AT ghodsroya impactofcovid19pandemiconscreeninganddiagnosisofpatientswithprostatecancerasystematicreviewprotocol AT madjdzahra impactofcovid19pandemiconscreeninganddiagnosisofpatientswithprostatecancerasystematicreviewprotocol |